CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab

References

• Swerdlow SH. World health organization, international agency for research on cancer. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th edition. Lyon: International Agency for Research on Cancer; 2017.
   Google Scholar
• Vaughn JL, Pinheiro LC, Olszewski A, et al. Survival of patients with marginal zone lymphoma in the United States: a population-based cohort study (2000 to 2017). Am J Hematol. 2021;96(4):E123–E126.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Rossi D, Paulli M. Splenic marginal zone lymphoma: from genetics to management. Blood. 2016;127(17):2072–2081.
   PubMed Web of Science ®Google Scholar
• Spina V, Khiabanian H, Messina M, et al. The genetics of nodal marginal zone lymphoma. Blood. 2016;128(10):1362–1373.
   PubMed Web of Science ®Google Scholar
• Kalpadakis C, Pangalis GA, Dimitriadou E, et al. Mutation analysis of IgVH genes in splenic marginal zone lymphomas: correlation with clinical characteristics and outcome. Anticancer Res. 2009;29(5):1811–1816.
   PubMed Web of Science ®Google Scholar
• Boveri E, Arcaini L, Merli M, et al. Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients. Ann Oncol. 2009;20(1):129–136.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Lazzarino M, Colombo N, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood. 2006;107(12):4643–4649.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Cascione L, Conconi A, et al. A MALT lymphoma prognostic index. Blood. 2017;130(12):1409–1417.
   PubMed Web of Science ®Google Scholar
• Alderuccio JP, Zhao W, Desai A, et al. Risk factors for transformation to Higher-Grade lymphoma and its impact on survival in a large cohort of patients with marginal zone lymphoma from a single institution. J Clin Oncol. 2018;36(34):3370–3380.
   Web of Science ®Google Scholar
• Alderuccio JP, Zhao W, Desai A, et al. Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation. Am J Hematol. 2019;94(5):585–596.
   PubMed Web of Science ®Google Scholar
• Salido M, Baro C, Oscier D, et al. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the splenic B-Cell lymphoma group. Blood. 2010;116(9):1479–1488.
   PubMed Web of Science ®Google Scholar
• Ruiz-Ballesteros E, Mollejo M, Rodriguez A, et al. Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood. 2005;106(5):1831–1838.
   PubMed Web of Science ®Google Scholar
• Rinaldi A, Mian M, Chigrinova E, et al. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood. 2011;117(5):1595–1604.
   PubMed Web of Science ®Google Scholar
• Dono M, Cerruti G, Zupo S. The CD5+ B-cell. Int J Biochem Cell Biol. 2004;36(11):2105–2111.
   PubMed Web of Science ®Google Scholar
• Li Y, Hu S, Zuo Z, et al. CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases. Mod Pathol. 2015;28(6):787–798.
   PubMed Web of Science ®Google Scholar
• Baseggio L, Traverse-Glehen A, Petinataud F, et al. CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases. Haematologica. 2010;95(4):604–612.
   PubMed Web of Science ®Google Scholar
• Jaso JM, Yin CC, Wang SA, et al. Clinicopathologic features of CD5-positive nodal marginal zone lymphoma. Am J Clin Pathol. 2013;140(5):693–700.
   PubMed Web of Science ®Google Scholar
• Ghione P, Bantilan KS, Joffe E, et al. CD5-Positive marginal zone lymphoma: Clinical characteristics of the MSKCC cohort, and comparison with the CD5-Negative population. Blood. 2020;136(Supplement 1):50–51.
   PubMedGoogle Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–1210.
   PubMed Web of Science ®Google Scholar
• Starr AG, Caimi PF, Fu P, et al. Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era. Br J Haematol. 2016;175(2):275–280.
   PubMed Web of Science ®Google Scholar
• Olszewski AJ, Ali S. Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma. Ann Hematol. 2014;93(3):449–458.
   PubMed Web of Science ®Google Scholar
• Kalpadakis C, Pangalis GA, Sachanas S, et al. Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance. Blood. 2018;132(6):666–670.
   PubMed Web of Science ®Google Scholar
• Iannitto E, Bellei M, Amorim S, et al. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. Br J Haematol. 2018;183(5):755–765.
   PubMed Web of Science ®Google Scholar
• Olszewski AJ, Butera JN, Reagan JL, et al. Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma. Am J Hematol. 2020;95(4):354–361.
   PubMed Web of Science ®Google Scholar
• Ollila TA, Olszewski AJ. Chemotherapy-free management of follicular and marginal zone lymphoma. CMAR. 2021;13:3935–3952.
   Google Scholar
• Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258–1265.
   PubMed Web of Science ®Google Scholar
• Patel N, Durkin L, Bodo J, et al. Immunohistochemical expression of lymphoid enhancer binding factor 1 in CD5-positive marginal zone, lymphoplasmacytic, and follicular lymphomas. Am J Clin Pathol. 2020;153(5):646–655.
   PubMed Web of Science ®Google Scholar
• Sorigue M, Magnano L, Miljkovic MD, et al. Positive predictive value of CD200 positivity in the differential diagnosis of chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2020;98(5):441–448.
   PubMed Web of Science ®Google Scholar
• Gailllard B, Cornillet-Lefebvre P, Le QH, Groupe Francophone de Cytogénétique Hématologique, et al. Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities. Br J Haematol. 2021;193(1):72–82.
   PubMed Web of Science ®Google Scholar
• Ferry JA, Yang WI, Zukerberg LR, et al. CD5+ extranodal marginal zone B-cell (MALT) lymphoma. A low grade neoplasm with a propensity for bone marrow involvement and relapse. Am J Clin Pathol. 1996;105(1):31–37.
   PubMed Web of Science ®Google Scholar
• Jaso J, Chen L, Li S, et al. CD5-positive mucosa-associated lymphoid tissue (MALT) lymphoma: a clinicopathologic study of 14 cases. Hum Pathol. 2012;43(9):1436–1443.
   PubMed Web of Science ®Google Scholar
• Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944–2952.
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Fink AM, Bahlo J, German CLL Study Group (GCLLSG), et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17(7):928–942.
   PubMed Web of Science ®Google Scholar
• Merryman RW, Edwin N, Redd R, et al. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020;4(5):858–867.
   PubMed Web of Science ®Google Scholar
• Olszewski AJ, Ollila TA, Reagan JL. Bendamustine-Rituximab does not improve survival over rituximab monotherapy for older patients with nodal or splenic marginal zone lymphoma. Blood. 2019;134(Supplement_1):2824–2824.
   Google Scholar
• Tadmor T, Polliack A. Nodal marginal zone lymphoma: clinical features, diagnosis, management and treatment. Best Pract Res Clin Haematol. 2017;30(1–2):92–98.
   PubMed Web of Science ®Google Scholar